276 related articles for article (PubMed ID: 24233555)
1. CD30: from basic research to cancer therapy.
Muta H; Podack ER
Immunol Res; 2013 Dec; 57(1-3):151-8. PubMed ID: 24233555
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin.
Ansell SM
Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
[TBL] [Abstract][Full Text] [Related]
3. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease.
Blazar BR; Levy RB; Mak TW; Panoskaltsis-Mortari A; Muta H; Jones M; Roskos M; Serody JS; Yagita H; Podack ER; Taylor PA
J Immunol; 2004 Sep; 173(5):2933-41. PubMed ID: 15322151
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
5. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
6. Role of CD30 targeting in malignant lymphoma.
Kumar A; Younes A
Curr Treat Options Oncol; 2014 Jun; 15(2):210-25. PubMed ID: 24570331
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
Hasanali ZS; Epner EM; Feith DJ; Loughran TP; Sample CE
Mol Cancer Ther; 2014 Dec; 13(12):2784-92. PubMed ID: 25319394
[TBL] [Abstract][Full Text] [Related]
9. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.
Blatt K; Cerny-Reiterer S; Schwaab J; Sotlar K; Eisenwort G; Stefanzl G; Hoermann G; Mayerhofer M; Schneeweiss M; Knapp S; Rülicke T; Hadzijusufovic E; Bauer K; Smiljkovic D; Willmann M; Reiter A; Horny HP; Valent P
Blood; 2015 Dec; 126(26):2832-41. PubMed ID: 26486787
[TBL] [Abstract][Full Text] [Related]
11. CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice.
Wang X; Gao Y; Zhang X; Wang X; Wang B; Meng X; Yoshikai Y; Wang Y; Sun X
Int Immunopharmacol; 2020 Jul; 84():106531. PubMed ID: 32353687
[TBL] [Abstract][Full Text] [Related]
12. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
[TBL] [Abstract][Full Text] [Related]
14. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV; Bartlett NL
Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
[TBL] [Abstract][Full Text] [Related]
16. CD30: an important new target in hematologic malignancies.
Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
[TBL] [Abstract][Full Text] [Related]
17. CD30-positive malignant lymphomas: time for a change of management?
Engert A
Haematologica; 2013 Aug; 98(8):1165-8. PubMed ID: 23904233
[No Abstract] [Full Text] [Related]
18. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
19. Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
Berger GK; Gee K; Votruba C; McBride A; Anwer F
Crit Rev Oncol Hematol; 2017 May; 113():8-17. PubMed ID: 28427526
[TBL] [Abstract][Full Text] [Related]
20. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
Nathwani N; Krishnan AY; Huang Q; Kim Y; Karanes C; Smith EP; Forman SJ; Sievers E; Thomas SH; Chen RW
Leuk Lymphoma; 2012 Oct; 53(10):2051-3. PubMed ID: 22369501
[No Abstract] [Full Text] [Related]
[Next] [New Search]